Skip to main content
. Author manuscript; available in PMC: 2017 Jul 3.
Published in final edited form as: J Heart Lung Transplant. 2016 Nov 10;36(5):546–553. doi: 10.1016/j.healun.2016.11.001

Table 2.

Patient Outcomes

Characteristic Overall, N (%) No Readmission, n (%) Readmission, n (%) p-valuea
Post-operative complications (short-term)
 Acute rental failure 103 (12.9) 59 (13.6) 44 (12.1) 0.5483
 Any infection 381 (47.9) 131 (44.0) 190 (52.6) 0.0154b
 Atrial fibrillation 263 (33.0) 130 (29.9) 133 (36.8) 0.0399b
 Pneumonia 241 (30.3) 114 (26.2) 127 (35.1) 0.0065b
 Pulmonary embolism 25 (3.1) 10 (2.3) 15 (4.1) 0.1365
 Sepsis 79 (9.9) 50 (11.5) 29 (8.0) 0.1017
 Stroke 25 (3.1) 18 (4.1) 7 (1.9) 0.0757
 Any complication 597 (75.0) 308 (70.9) 289 (80.0) 0.0032b
Long-term complications
 Mortality
  1-year (n = 688) 70 (10.1) 39 (10.6) 31 (9.6) 0.6936
  3-year (n = 525) 144 (27.3) 73 (26.6) 71 (28.2) 0.6731
  5-year (n = 433) 199 (45.9) 98 (44.3) 101 (47.6) 0.4910
 Dialysis 96 (12.0) 45 (10.3) 51 (14.1) 0.1054
 CKD3+ (6 months) 509 (68.6) 251 (63.5) 258 (74.3) 0.0016b
  No. unknown 53
 Non-skin malignancy 189 (23.7) 98 (22.5) 91 (25.2) 0.3863

CKD3+, chronic kidney disease stage 3 or worse.

a

Chi-square or t-test. Statistically significant at 5% level.

b

Statistically significant at the 5% level.